Naldemedine
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | None |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
916072-89-4 1345728-04-2 (tosylate) |
| PubChem (CID) | 135626906 |
| ChemSpider | 28530803 |
| Chemical and physical data | |
| Formula | C32H34N4O6 |
| Molar mass | 570.63556 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting.[1][2][3] Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.<ref name="Sprawls1997" /[2] No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed.[1] As of July 2014, naldemedine is in phase III clinical trials in the United States and Japan.
See also
References
- 1 2 De Sarro, Giovambattista; Kelly S. Sprawls; Egilius L.H. Spierings; Dustin Tran (2012-03-07). "Drugs in Development for Opioid-Induced Constipation" (PDF). In Catto-Smith G., Anthony. Constipation - Causes, Diagnosis and Treatment. p. 7. doi:10.5772/30377. ISBN 978-953-51-0237-3. Retrieved 12 May 2012.
- 1 2 Shionogi (2009-03-27). "Research and Development at Shionogi (as of March 2009)" (PDF). Retrieved 2012-05-12.
- ↑ Nagase H, Fujii H (2011). "Opioids in preclinical and clinical trials". Topics in Current Chemistry. 299: 29–62. doi:10.1007/128_2010_74. PMID 21630515.
This article is issued from Wikipedia - version of the 6/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.